To Validate or Not To Validate: A Daily Question for the Pharmaceutical Scientist
Kim Huynh-Ba
90 Min
Product Id: 702386
This 90-minute webinar will outline the common deficiencies in relation to method validation, for pharmaceutical products, outline regulatory requirements and the change control process needed to stay in compliance.
Biomarkers for Drug Development: The Emerging Regulatory Landscape
Orest Hurko
60 Min
Product Id: 702396
This training provides an up-to-date understanding of regulatory requirements for the development and implementation of biomarkers in drug development programs, as well as highlights of the most recent FDA sources on general, imaging (Including PET) and pharmacogenomic biomarkers.
Pharmaceutical Water System Use & Monitoring
T.C Soli
90 Min
Product Id: 702265
This webinar on pharmaceutical water systems will explain practical best practices for outlet use and sampling to reflect the true water quality and how to most effectively use the resulting data to improve manufacturing’s water use practices and maintain water system control before problems arise from biofilm-related contamination.
Full Day Virtual Seminar: Understanding and Effectively Controlling Biofilm in Pharmaceutical Water Systems
T.C Soli
6 hrs
Product Id: 701981
This 6-hr training will focus on important microbial issues with pharmaceutical water systems and provide proven solutions for microbial control. Attendees will learn effective sanitation and validation approaches to successfully control biofilm in water systems.
FDA's Regulation of Veterinary Regenerative Medicine: What Industry Needs to Know to Market and Sell a Stem Cell Product for Use in Dogs, Cats, Horses and other Animals
Karl M. Nobert
60 Min
Product Id: 702322
This webinar will provide an introduction to FDA’s regulation of veterinary regenerative medicine and highlight the regulatory requirements that a biotech company needs to satisfy to commercialize a stem cell or other complex biotech product for animal use in the U.S.
REMS Update: Risk Evaluation and Mitigation Strategies - what do you need to do now?
Orest Hurko
60 Min
Product Id: 702316
This webinar on Risk Evaluation and Mitigation Strategy (REMS) will help you understand how to adhere to REMS policy, its implementation and submission requirements. It will discuss FDA's current thinking on REMS, how it reduces the REMS obligations for sponsors, and how the agency's requirements and procedures in this area are evolving.
Unsolicited Drug and Device Off-Label Claims Via Social Media and Risk Management
Charles R. McConachie
60 Min
Product Id: 702334
This course will provide necessary information to those in the drug and device manufacturing industries on how to best work with consumers and health professionals regarding off-label claims of relevant drugs and devices that arise from third parties or from the natural progression of social media.
QbD Approach to Analytical Method Lifecycle: Design, Development, Validation, Transfer
Gregory Martin
120 Min
Product Id: 702278
This 120-minute webinar on using the QbD Approach to Analytical Method Lifecycle is designed to provide participants with a lifecycle approach to developing and validating analytical methods and comply with compendial requirements.
Dissolution Instrument Qualification to Meet Requirements and Minimize Product OOS Dissolution Results
Gregory Martin
120 Min
Product Id: 701917
This 2-hr Dissolution Instrument Qualification webinar will discuss recent FDA requirements for dissolution instrument qualification and provide practical suggestions to avoid pitfalls in performance of the tests, minimize Performance Verification Test and product failures.
3-hr Virtual Seminar: An Introduction to the FDA New Drug Approval Process
Karl M. Nobert
3 hrs
Product Id: 702207
This 3-hr virtual seminar on the FDA New Drug Approval Process will cover the NDA and ANDA review and approval process including a discussion of preparing NDAs and ANDAs, relevant meetings, timing, costs, approval requirements and other FDA regulatory requirements. The various existing regulatory approval pathways (the “full” NDA, the 505(b)(2) NDA and the ANDA) will be discussed.
Full day Virtual Seminar: Drug Master Files - Understanding and Meeting your Global Regulatory and Processing Responsibilities
Robert J Russell
6 hrs
Product Id: 702039
This DMFs (Drug Master Files) training will discuss the current review and enforcement climate within FDA and the manner in which drug master files (DMFs) are reviewed by FDA personnel. Besides the US, the use of DMFs in the EU, Japan, Canada and Australia will also be discussed. Similarities and differences to the U.S. system will be highlighted.
Dry Powder Inhalers II: Enhancing bioavailability through product design
Claudio Cerati
85 Min
Product Id: 702013
This webinar on Dry Powder Inhalers will focus on pharmaceutical active particle design, physical characteristics and its relationship with product behavior both in vitro and in vivo.
4-hr Virtual Seminar : A Comparison of ICH Q-10 Quality System and the FDA's Quality Systems Approach (QSA) to the Pharmaceutical cGMPs
Howard Cooper
3.5 hrs
Product Id: 701973
This webinar will help you understand the current quality and regulatory paradigm by comparing and analyzing ICH-Q10 Pharmaceutical Quality System and the FDA’s Quality Systems Approach (FQSA) to Pharmaceutical GMPs.
Avoiding Failure to Investigate - Observations by Conducting Effective Investigations
Felicia Ford-Rice
49 Min
Product Id: 701933
This webinar will focus on the key attributes of an effective cGMP investigation, the role of management, employing quality control tools, CAPA effectiveness checks and Warning Letters associated with cGMP compliance. Attend this training and learn how you can avoid “Failure to Investigate" Observations by FDA.
Acceptance Sampling Plans for Process Validation and Production Lot Monitoring
Steven Wachs
90 Min
Product Id: 704315
This webinar provides details regarding the generation of acceptance sampling plans often used in process validation and production control to ensure quality of final products. By attending this webinar, participants will be able understand the key inputs and issues involved in determining acceptance sampling plans. Sampling plans for attribute data are the primary focus although variable acceptance sampling plans are presented as well.
Objectionable Microorganisms: Considering the Risk
Frank Settineri
90 Min
Product Id: 701313
This Objectionable Microorganism training will explore the most current practices that define an objectionable microorganism and will provide a practical approach to determining just how objectionable it really is.
Japanese PAL - JPAL change notifications and reporting between the foreign manufacturer, MAH and PMDA
Phil Smart
90 Min
Product Id: 701291
This JPAL (Japanese Pharmaceutical Affairs Law) training will go into the unique post-market challenge of change management facing the Foreign Manufacturer when dealing with its MAH counterpart in Japan.
Ensuring the Microbiological Integrity of Pharmaceutical and Biopharmaceutical Facilities
Frank Settineri
90 Min
Product Id: 701145
This Microbiology training/webinar will provide a new approach in ensuring the Microbiological Integrity of Pharmaceutical and Biopharmaceutical Facilities.
Japanese PAL - Navigating the Japanese Pharmaceutical Affairs Law
Phil Smart
90 Min
Product Id: 701276
This JPAL training will emphasize on Japanese Pharmaceutical Affairs law with respect to - Classification, device approvals, clinical data, MAH (Marketing Authorization Holder),foreign manufacturer accreditation,QMS,post-market complaints & vigilance
Maintenance and Calibration of Equipment
Michelle Sceppa
60 Min
Product Id: 701188
This Pharmaceutical compliance training will provide instruction on how to establish and maintain a Maintenance & Calibration program for pharmaceutical instrumentation & equipment.